ES2821529T3 - Derivados de 4,6-diamino-pirimidina como inhibidores de Bmi-1 para el tratamiento del cáncer - Google Patents

Derivados de 4,6-diamino-pirimidina como inhibidores de Bmi-1 para el tratamiento del cáncer Download PDF

Info

Publication number
ES2821529T3
ES2821529T3 ES13857326T ES13857326T ES2821529T3 ES 2821529 T3 ES2821529 T3 ES 2821529T3 ES 13857326 T ES13857326 T ES 13857326T ES 13857326 T ES13857326 T ES 13857326T ES 2821529 T3 ES2821529 T3 ES 2821529T3
Authority
ES
Spain
Prior art keywords
diamine
fluoro
benzoimidazol
alkyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13857326T
Other languages
English (en)
Spanish (es)
Inventor
Chang-Sun Lee
Ramil Baiazitov
Liangxian Cao
Thomas Davis
Wu Du
Ronggang Liu
Young-Choon Moon
Steven Paget
Hongyu Ren
Nadiya Sydorenko
Richard Wilde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Application granted granted Critical
Publication of ES2821529T3 publication Critical patent/ES2821529T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
ES13857326T 2012-11-21 2013-11-21 Derivados de 4,6-diamino-pirimidina como inhibidores de Bmi-1 para el tratamiento del cáncer Active ES2821529T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261728907P 2012-11-21 2012-11-21
PCT/US2013/071132 WO2014081906A2 (en) 2012-11-21 2013-11-21 Substituted reverse pyrimidine bmi-1 inhibitors

Publications (1)

Publication Number Publication Date
ES2821529T3 true ES2821529T3 (es) 2021-04-26

Family

ID=50776672

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13857326T Active ES2821529T3 (es) 2012-11-21 2013-11-21 Derivados de 4,6-diamino-pirimidina como inhibidores de Bmi-1 para el tratamiento del cáncer

Country Status (32)

Country Link
US (3) US10428050B2 (enExample)
EP (1) EP2922828B1 (enExample)
JP (3) JP6412503B2 (enExample)
KR (4) KR20220143164A (enExample)
CN (2) CN111423417B (enExample)
AR (1) AR093579A1 (enExample)
AU (1) AU2013348009C1 (enExample)
BR (1) BR112015011760B1 (enExample)
CA (1) CA2892045C (enExample)
CL (1) CL2015001377A1 (enExample)
CR (1) CR20150294A (enExample)
CU (1) CU24387B1 (enExample)
DK (1) DK2922828T3 (enExample)
EA (2) EA035349B1 (enExample)
EC (1) ECSP15019948A (enExample)
ES (1) ES2821529T3 (enExample)
HK (1) HK1215032A1 (enExample)
IL (2) IL238871B (enExample)
MA (1) MA38208B1 (enExample)
MX (2) MX385385B (enExample)
NI (1) NI201500072A (enExample)
NZ (2) NZ708909A (enExample)
PE (1) PE20151413A1 (enExample)
PH (1) PH12015501130B1 (enExample)
PL (1) PL2922828T3 (enExample)
PT (1) PT2922828T (enExample)
SA (1) SA517381847B1 (enExample)
SG (2) SG10201600149VA (enExample)
TW (1) TWI623531B (enExample)
UA (1) UA118094C2 (enExample)
WO (1) WO2014081906A2 (enExample)
ZA (1) ZA201503642B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220143164A (ko) * 2012-11-21 2022-10-24 피티씨 테라퓨틱스, 인크. 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
CA2917671A1 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2922657C (en) * 2013-08-30 2022-04-12 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
CN108351862B (zh) 2015-08-11 2023-08-22 科格诺亚公司 利用人工智能和用户输入来确定发育进展的方法和装置
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
US20190016680A1 (en) * 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
CN118609834A (zh) 2016-11-14 2024-09-06 科格诺亚公司 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置
JP7324709B2 (ja) 2017-02-09 2023-08-10 コグノア，インク． デジタル個別化医療のためのプラットフォームとシステム
KR20200035292A (ko) 2017-08-01 2020-04-02 피티씨 테라퓨틱스, 인크. 혈액 암 치료에 사용하기 위한 dhodh 억제제
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
BR112021002630A2 (pt) * 2018-08-17 2021-05-11 Ptc Therapeutics, Inc. método para tratar câncer pancreático
CN109988172B (zh) * 2019-01-10 2020-09-29 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
US20220096473A1 (en) * 2019-01-15 2022-03-31 Ptc Therapeutics, Inc. Method for treating an acute myeloid leukemia
BR112021016747A2 (pt) * 2019-02-28 2021-10-19 Ptc Therapeutics, Inc. Método para tratamento de um meloma múltiplo
EA202192167A1 (ru) * 2019-03-11 2022-01-12 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Форма соединения, обладающая повышенной биодоступностью, и ее составы
EP3941340A4 (en) 2019-03-22 2022-11-30 Cognoa, Inc. Personalized digital therapy methods and devices
CN114096537B (zh) * 2019-03-27 2025-01-10 Ptc医疗公司 肉瘤治疗方法的有用组合
CN111793031B (zh) * 2019-04-02 2021-06-22 海创药业股份有限公司 芳香胺类化合物及其在制备ar和brd4双重抑制剂和调控剂中的用途
TWI843989B (zh) 2021-02-19 2024-06-01 美商美威高能離子醫療系統公司 用於粒子治療系統之支架
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (enExample) * 1973-09-20 1977-11-30 Delalande Sa
JP2896532B2 (ja) 1994-08-13 1999-05-31 ユーハン コーポレーション 新規なピリミジン誘導体およびその製造方法
IN188411B (enExample) 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
EP1206265B1 (en) 1999-06-30 2003-11-12 Merck & Co., Inc. Src kinase inhibitor compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
ES2306671T3 (es) 1999-10-07 2008-11-16 Amgen Inc. Inhibidores de triazina quinasa.
EP1224185B1 (en) 1999-10-27 2005-11-30 Novartis AG Thiazole and imidazo[4,5-b]pyridine compounds and their pharmaceutical use
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
JP5074653B2 (ja) 2000-03-29 2012-11-14 サイクラセル リミテッド ２−置換４−ヘテロアリール−ピリミジンおよび増殖性障害におけるその使用
AU2001296871A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
PT1330452E (pt) 2000-09-20 2009-01-22 Ortho Mcneil Pharm Inc Derivados de pirazina como moduladores de tirosina-cinases
EP1351691A4 (en) * 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
AU2002239348A1 (en) 2000-12-15 2002-06-24 Glaxo Group Limited Pyrazolopyridine derivatives
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
ATE416175T1 (de) 2001-02-20 2008-12-15 Astrazeneca Ab 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen
CA2439263C (en) 2001-03-02 2012-10-23 Frank Becker Three hybrid assay system
WO2003000682A1 (en) 2001-06-25 2003-01-03 Merck & Co., Inc. (pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
DE60214198T2 (de) 2001-07-03 2007-08-09 Vertex Pharmaceuticals Inc., Cambridge Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
WO2003011837A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003075828A2 (en) 2002-03-11 2003-09-18 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
CA2486187C (en) 2002-05-23 2013-02-19 Cytopia Pty Ltd. Kinase inhibitors
RU2315043C2 (ru) 2002-06-28 2008-01-20 Ниппон Синяку Ко., Лтд. Амидное производное, фармацевтическая композиция и терапевтические средства на его основе
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004007407A2 (en) * 2002-07-11 2004-01-22 Fluorous Technologies Incorporated Fluorous tagging and scavenging reactants and methods of synthesis and use thereof
US20040110821A1 (en) * 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
JP2006504755A (ja) 2002-10-15 2006-02-09 スミスクライン ビーチャム コーポレーション Ｇｓｋ−３阻害薬としてのピリダジン化合物
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
GB2432834A (en) 2004-01-12 2007-06-06 Cytopia Res Pty Ltd Selective Kinase Inhibitors
US20070117818A1 (en) 2004-02-04 2007-05-24 Masaichi Hasegawa Pyrimidinone compounds useful as kinase inhibitors
WO2005095400A1 (en) 2004-03-30 2005-10-13 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
AU2006219231B2 (en) 2005-02-28 2010-01-14 Japan Tobacco Inc. Novel aminopyridine compound with Syk inhibitory activity
CA2601257A1 (en) 2005-03-10 2006-09-21 Bayer Pharmaceuticals Corporation Pyrimidine derivatives for treatment of hyperproliferative disorders
DE602007004618D1 (de) 2006-06-22 2010-03-18 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren
MX2009003142A (es) 2006-10-03 2009-04-06 Neurosearch As Derivados de indazolilo utiles como agentes moduladores del canal de potasio.
CN101516873A (zh) * 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
ES2383370T3 (es) 2006-10-19 2012-06-20 Signal Pharmaceuticals Llc Compuestos de heteroarilo, sus composiciones y uso de los mismos como inhibidores de proteína quinasa
WO2008079933A2 (en) 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections
TW200902010A (en) 2007-01-26 2009-01-16 Smithkline Beecham Corp Anthranilamide inhibitors of aurora kinase
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
UY31048A1 (es) 2007-04-25 2008-11-28 Astrazeneca Ab Nuevos compuestos de pirimidina y usos de los mismos
GB0714573D0 (en) 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
WO2009037247A1 (en) 2007-09-17 2009-03-26 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
CN101910152B (zh) 2007-11-16 2014-08-06 因塞特公司 作为janus激酶抑制剂的4-吡唑基-n-芳基嘧啶-2-胺和4-吡唑基-n-杂芳基嘧啶-2-胺
KR20100098521A (ko) 2007-12-07 2010-09-07 노파르티스 아게 피라졸 유도체 및 그의 사이클린 의존성 키나제 억제제로서의 용도
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
US8258144B2 (en) 2008-04-22 2012-09-04 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2010002985A1 (en) * 2008-07-01 2010-01-07 Ptc Therapeutics, Inc. Bmi-1 protein expression modulators
CA2731368C (en) 2008-08-06 2013-05-14 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
EP2331527A1 (en) 2008-09-02 2011-06-15 NeuroSearch A/S Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
WO2010061903A1 (ja) * 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
WO2010092962A1 (ja) 2009-02-12 2010-08-19 アステラス製薬株式会社 へテロ環誘導体
JP5766177B2 (ja) 2009-03-27 2015-08-19 ベトディーシー，インコーポレイテッド ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
US8536180B2 (en) 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
TW201102387A (en) 2009-06-08 2011-01-16 Medicinova Inc Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity
AU2010262905B2 (en) * 2009-06-17 2015-04-16 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EP2532659A1 (en) 2009-07-07 2012-12-12 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
JP2012533553A (ja) 2009-07-15 2012-12-27 アボット・ラボラトリーズ ピロロピリジン系キナーゼ阻害薬
ES2483594T3 (es) 2009-07-15 2014-08-06 Abbott Laboratories Pirrolopirazinas inhibidoras de quinasas
JP2011136925A (ja) * 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
AU2011206621B2 (en) 2010-01-12 2016-04-14 Ab Science Thiazole and oxazole kinase inhibitors
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
RU2562111C2 (ru) * 2010-08-19 2015-09-10 Ф.Хоффманн-Ля Рош Аг Конверсия соматических клеток в индуцированные репрограмированные нейрональные стволовые клетки (ирнск)
RS54544B1 (sr) 2010-09-13 2016-06-30 Novartis Ag Triazin-oksadiazoli
US20140088056A1 (en) * 2010-09-28 2014-03-27 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
AU2011338389A1 (en) 2010-12-09 2013-06-13 Amgen Inc. Bicyclic compounds as Pim inhibitors
US9890138B2 (en) 2011-02-25 2018-02-13 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof
WO2013004332A1 (en) * 2011-07-07 2013-01-10 Merck Patent Gmbh Substituted azaheterocycles for the treatment of cancer
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
KR20220143164A (ko) * 2012-11-21 2022-10-24 피티씨 테라퓨틱스, 인크. 치환된 리버스 피리미딘 ｂｍｉ-1 저해제
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
EA202192167A1 (ru) * 2019-03-11 2022-01-12 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Форма соединения, обладающая повышенной биодоступностью, и ее составы

Also Published As

Publication number Publication date
NZ708909A (en) 2019-11-29
US20200024260A1 (en) 2020-01-23
CR20150294A (es) 2015-08-20
JP2020055815A (ja) 2020-04-09
CN111423417B (zh) 2022-11-15
JP6617186B2 (ja) 2019-12-11
US11180483B2 (en) 2021-11-23
EP2922828A2 (en) 2015-09-30
IL265253A (en) 2019-05-30
EA201590992A1 (ru) 2015-11-30
TWI623531B (zh) 2018-05-11
US20220064150A1 (en) 2022-03-03
KR102275676B1 (ko) 2021-07-12
CU20150053A7 (es) 2015-11-27
BR112015011760B1 (pt) 2022-12-06
BR112015011760A2 (pt) 2017-07-11
KR102356487B1 (ko) 2022-02-08
US10428050B2 (en) 2019-10-01
SA517381847B1 (ar) 2021-07-17
WO2014081906A2 (en) 2014-05-30
PH12015501130B1 (en) 2023-01-27
CA2892045A1 (en) 2014-05-30
JP2019031509A (ja) 2019-02-28
EP2922828A4 (en) 2016-07-27
AU2013348009C1 (en) 2019-08-08
KR20220143164A (ko) 2022-10-24
EA201890142A1 (ru) 2018-06-29
NZ746607A (en) 2019-11-29
KR20150086345A (ko) 2015-07-27
PT2922828T (pt) 2020-10-12
KR20220016305A (ko) 2022-02-08
KR20210088740A (ko) 2021-07-14
ECSP15019948A (es) 2016-01-29
SG10201600149VA (en) 2016-02-26
SG11201503982XA (en) 2015-06-29
HK1215032A1 (zh) 2016-08-12
AU2013348009B2 (en) 2018-05-17
US20150315182A1 (en) 2015-11-05
JP6918898B2 (ja) 2021-08-11
EA031405B1 (ru) 2018-12-28
IL238871A0 (en) 2015-07-30
EP2922828B1 (en) 2020-07-08
IL238871B (en) 2019-03-31
ZA201503642B (en) 2020-10-28
AR093579A1 (es) 2015-06-10
DK2922828T3 (da) 2020-08-31
EA035349B1 (ru) 2020-05-29
MA38208B1 (fr) 2021-12-31
UA118094C2 (uk) 2018-11-26
MX2021009892A (es) 2021-09-14
CU24387B1 (es) 2019-03-04
MX2015006469A (es) 2015-10-29
PL2922828T3 (pl) 2020-12-28
CA2892045C (en) 2022-05-31
NI201500072A (es) 2016-01-18
AU2013348009A1 (en) 2015-06-04
PE20151413A1 (es) 2015-10-23
WO2014081906A3 (en) 2014-07-17
CL2015001377A1 (es) 2016-02-19
JP2016504290A (ja) 2016-02-12
KR102455889B1 (ko) 2022-10-17
MX385385B (es) 2025-03-18
PH12015501130A1 (en) 2015-08-03
TW201427972A (zh) 2014-07-16
JP6412503B2 (ja) 2018-10-24
CN111423417A (zh) 2020-07-17
CN104918919A (zh) 2015-09-16

Similar Documents

Publication Publication Date Title
ES2821529T3 (es) Derivados de 4,6-diamino-pirimidina como inhibidores de Bmi-1 para el tratamiento del cáncer
US10370371B2 (en) Substituted pyrimidine Bmi-1 inhibitors
US9975878B2 (en) Substituted triazine BMI-1 inhibitors
HK40034027B (en) Substituted reverse pyrimidine bmi-1 inhibitors
BR112016004511B1 (pt) Composto, composto ou uma forma do mesmo, uso de um composto ou forma do mesmo, e composição farmacêutica para uso no tratamento de um câncer mediado por bmi-1